We have shown that both bepridil (this study) and quinidine11 exacerbate the seizure phenotype in our Drosophila models of KCNT1 epilepsy, most likely by inhibiting other cation channels that control neuronal excitability, highlighting the value of in vivo preclinical analysis for drug repurposing. Here, KCNT1 is linked to epilepsy.